Active Ingredient: ROTIGOTINE
In a thorough QT study involving patients with Parkinson’s disease, doses were escalated weekly up to a supratherapeutic level of 24 mg/24 h. The differences in QTc between rotigotine and placebo remained close to zero, with the upper one-sided 95% CI staying below 5 ms (well under the 10 ms regulatory threshold).
https://doi.org/10.1038/clpt.2008.143